Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, in Participants With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CS 2009 (Primary)
  • Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors CStone Pharmaceuticals

Most Recent Events

  • 04 Mar 2025 According to CStone Pharmaceuticals media release, company announced that the global multi-center Phase I clinical trial of CS2009, has successfully completed the dosing of the first patient without infusion reactions or other adverse events.
  • 03 Mar 2025 According to CStone Pharmaceuticals media release, company announced that the first patient has been successfully dosed in the global multicenter Phase I clinical trial of its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, with no infusion reactions or other adverse events observed. Also the company look forward to sharing additional clinical data that will further validate its safety and anti-tumor activity.
  • 03 Mar 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top